Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||no benefit||Bevacizumab + Docetaxel||Phase III||Actionable||In a Phase III trial, treatment with Avastin (bevacizumab) combined with Taxotere (docetaxel) in mCRPC patients did not result in an improved OS (22.6 mo vs 21.5 mo) and demonstrated increased toxicities when compared to Taxotere (docetaxel) plus placebo (PMID: 22454414).||22454414|